1-MIN READ

Gilead's Anti-viral Drug Remdesivir Endorsed as First Coronavirus Treatment in Europe

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo

The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended the drug's use in adults and adolescents from 12 years of age with pneumonia who require oxygen support.

  • Reuters
  • Last Updated: June 25, 2020, 9:08 PM IST
Share this:

The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc's antiviral treatment, remdesivir, for use in COVID-19 patients, making it the first treatment to be on track to be green-lit in the continent.

The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended the drug's use in adults and adolescents from 12 years of age with pneumonia who require oxygen support.

The price of the drug in the region is not yet known. In the United States, it could be priced up to $5,080 per course, while Indian generic drugmakers will sell the treatment between 5,000 rupees to 6,000 rupees ($66.13-$79.35).

The EMA endorsement, which comes just weeks after a speedy review, means physicians can prescribe the Gilead drug, to be branded Veklury, in Europe once approved by the European Commission, which usually follows CHMP recommendations.

The EU's conditional marketing authorisation allows a treatment to be sold for a year in the 27-nation trading bloc before all necessary data on its efficacy and side-effects are available. Gilead has to submit final data by December.

Demand for the drug soared after it became a front-runner following promise in trials. Gilead expects supply of remdesivir to exceed two million courses by year-end, double its previous target, and is planning to begin testing of an easier-to-use inhaled version of the drug, given intravenously as of now.

Remdesivir has already been approved for emergency use in severely-ill patients in the United States, India and South Korea, and has received full approval in Japan.

Next Story
Loading